Research programme: cancer therapeutics - CK Life Sciences

Drug Profile

Research programme: cancer therapeutics - CK Life Sciences

Alternative Names: CKBP 002; CKBP 004

Latest Information Update: 06 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CK Life Sciences
  • Developer Cedars-Sinai Health System; CK Life Sciences; University of California at Los Angeles
  • Class
  • Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors; Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 06 Jul 2011 Preclinical development is ongoing in Hong Kong and USA
  • 16 Apr 2008 Pharmacodynamics data from a Preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
  • 08 May 2007 Preclinical trials in Solid tumours in Hong Kong (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top